{"id":"NCT03100500","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Long-term Safety Study of QMF149 in Japanese Participants With Asthma","officialTitle":"A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QMF149 in Japanese Patients With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-25","primaryCompletion":"2018-07-19","completion":"2019-02-12","firstPosted":"2017-04-04","resultsPosted":"2020-02-07","lastUpdate":"2020-02-07"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"QMF149","otherNames":[]}],"arms":[{"label":"QMF149","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to provide long term safety data of QMF149 in Japanese participants with inadequately controlled asthma for the registration of QMF149 in Japan.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to 52 weeks","effectByArm":[{"arm":"QMF-149 150/320 Î¼g","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":15,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Asthma","Nasopharyngitis","Bronchitis","Upper respiratory tract infection bacterial","Back pain"]}}